<DOC>
	<DOCNO>NCT00665145</DOCNO>
	<brief_summary>The primary secondary objective study : Primary : To evaluate stem-cell-mobilization subject diabetic neuropathy receive SB-509 . Stem cell mobilization assess evaluate presence stem cell circulate peripheral blood . Secondary : To evaluate safety SB-509 subject treat SB-509 diabetic neuropathy ; compare effect SB-509 versus placebo pre-defined multi-endpoint analysis include visual analog scale pain intensity ( VASPI ) , total neuropathy score ( TNS ) , evoke nerve conduction velocity ( NCV ) quantitative sensory testing ( QST )</brief_summary>
	<brief_title>Stem Cell Mobilization Diabetic Neuropathy Subjects Receiving SB-509</brief_title>
	<detailed_description>SB-509 contains gene ( DNAâ€”a kind biological `` blueprint '' ) protein . When researcher inject SB-509 leg , drug enters muscle nerve cell around injection site cause cell make protein . This protein cause cell increase production another protein call vascular endothelial growth factor ( VEGF ) , may improve structure function nerve . In addition , change level 28 additional protein cell . These protein function promote growth cell , structure cell , help synthesize product , affect immune cell , unknown function . This increase VEGF proteins may protect repair damaged nerve cause diabetic neuropathy . This study intend evaluate mechanism SB-509 action .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Key Have clinical diagnosis diabetes mellitus type I II least 12 month prior study . Have receive diagnosis sensorimotor diabetic neuropathy neurologist ( doctor specialize disorder nervous system ) endocrinologist ( doctor specialize diabetes ) . Have reduce nerve conduction velocity low extremity nerve : peroneal , tibial sural due diabetic polyneuropathy If female childbearing potential , agree use medically acceptable physical barrier method study . Have blood pressure &lt; 140/90 mm Hg Body mass index ( BMI ) &lt; 38 kg/m2 Key Subjects follow NOT eligible participate study : Have moderate severe ischemic heart disease , history congestive heart failure , myocardial infarction ( heart attack ) within previous 6 month . Have chronic foot leg ulcer &gt; 1 month , gangrene leg , previous amputation lower extremity . Have history cancer within past 5 year ( except curable nonmelanoma cancer skin , superficial bladder cancer complete remission , cancer complete remission least 5 year ) . Have colon polyp . If patient history benign colonic polyp remove , must evidence normal colonoscopy within last 12 month . Require drug depress patient ' immune system ( methotrexate , cyclophosphamide , cyclosporine ) receive study drug 30 day afterwards . Have know disorder affect patient ' immune system ( HIV/AIDS , hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] , sarcoidosis , tuberculosis , rheumatoid arthritis , autoimmune disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetic Polyneuropathy</keyword>
	<keyword>Stem Cells</keyword>
</DOC>